




Anna M. Mandalakas,*† Christopher Kippes,†
Joseph Sedransk,* Jeffery R. Kile,* Asha Garg,*
John McLeod,† Richard L. Berry,‡ 
and Anthony A. Marfin§
Serum samples and sociodemographic data were
obtained from 1,209 Ohio residents. West Nile virus
immunoglobulin M (IgM) and IgG antibodies were detected
by enzyme-linked immunosorbent assay and confirmed.
Children were 4.5 times more likely to become infected yet
110 times less likely to have neuroinvasive disease develop. 
S
ince its 1999 North American introduction, West Nile
virus (WNV) has emerged as an important cause of ill-
ness and death. Although several at-risk populations have
been identified, older age remains the major risk factor for
developing encephalitis after infection (1–4). 
WNV rapidly spread across the United States, resulting
in intense epidemic activity in Louisiana, Illinois,
Michigan, and Ohio in 2002; Colorado in 2003; and
Arizona and California in 2004 (5,6). In Ohio, WNV infec-
tions were first recognized in animals in 2001. In 2002,
Ohio reported 341 human cases of WNV encephalitis or
meningitis (West Nile neuroinvasive disease [WNND],
incidence: 28 cases/million population) with 31 deaths. In
2002, Cleveland and surrounding Cuyahoga County (2000
population 1,393,978 of whom 1,302,982 were >5 years of
age) reported 221 laboratory-confirmed cases of WNV ill-
ness, including 155 WNND cases (111 cases/million pop-
ulation) with 11 deaths from July 30 to October 3. All
reported WNND patients (median age 61 years, range
11–98 years) were hospitalized (CDC ArboNET
Surveillance Network, unpub. data).
Since most WNV infections are asymptomatic (7,8),
the true rate of WNV infection can best be estimated by
measuring the prevalence of WNV-specific antibody in a
recently exposed population. In December 2002, the
Cuyahoga County public health community conducted a
household-based seroprevalence survey to estimate neigh-
borhood and countywide WNV infection rates.
The Study
The survey was conducted December 5–12, 2002.
Stratified multistage cluster sampling was used to estimate
countywide and subpopulation prevalence rates. The coun-
ty was divided into 3 risk strata (Table 1). Census tracts
were sampled within strata with probability proportional to
population. Within each census tract, clusters of ≈50
households were formed. At random points, residents were
approached for recruitment until 10 participating house-
holds were enrolled from each cluster. 
Residents >5 years of age who had lived in the house-
hold since July 1, 2002, were asked to participate by pro-
viding a blood sample and responding to a questionnaire.
One person from each household completed a question-
naire about the home environment. Questionnaires devel-
oped by the Centers for Disease Control and Prevention
(CDC) were used (10). Informed consent was obtained
from all participants or their legal guardian. Assent was
obtained from minors >8 years of age. Residents were
offered a US $10 gift certificate and test results as compen-
sation. Persons who were pregnant, mentally handicapped,
or taking anticoagulants were not enrolled. Institutional
review board approval was obtained from University
Hospitals of Cleveland. 
Serum samples were screened with a WNV-specific
immunoglobulin M (IgM) antibody-capture (MAC)
enzyme-linked immunosorbent assay (ELISA) (11) and
indirect IgG ELISA at Focus Laboratories (Cypress, CA,
USA). Positive IgM and IgG were defined as an antibody
index >2.0 and >0.9, respectively. All IgM- and IgG-posi-
tive samples were sent to the Viral and Rickettsial
Laboratory, California Department of Health Services
(Richmond, CA, USA) for confirmatory plaque reduction
neutralization tests to identify WNV and St. Louis
encephalitis virus (SLEV)–specific neutralizing antibody.
At the second laboratory, WNV MAC-ELISAs (12) were
repeated and IgG ELISAs for WNV, SLEV, and dengue
were performed (13). Laboratory-based case definitions
were developed (Table 2). 
SPSS version 11.5 (SPSS Inc, Chicago, IL, USA) and
SUDAAN version 8.0 (Research Triangle Institute,
Research Triangle Park, NC, USA) were used for prelimi-
nary analyses and to assess differences in demographics,
behavior, and clinical characteristics between seropositive
and seronegative persons. Since SUDAAN variance esti-
mation did not accommodate our complex sample design,
we developed formulas to provide better estimates of vari-
ance and confidence intervals (CIs) using an α = 0.05.
Unless noted, all analyses were weighted. Individual
weights were derived by taking the inverse of the probabil-
ity of selection.
The standard Horvitz-Thompson estimator was used
for point estimation (14). For variance estimates, all
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process were included by using standard Taylor series
approximations. To calculate the confidence interval for
the true prevalence ratio (PR), we approximated the vari-
ance of the logarithm of the sample PR by using standard
Taylor series method. The end points of this interval were
exponentiated to obtain the interval for PR. 
Conclusions
Participants were recruited from 13 Cuyahoga County
municipalities and 9 Cleveland neighborhoods. Of 4,676
households visited, 2,318 households had an eligible adult
present; of these eligible households, 819 households
(35.3%) agreed to participate. Of 1,747 eligible residents
in 819 households, 1,251 (71.6%) consented to participate;
42 participants in 13 households had insufficient serum
samples and were excluded. The study sample consisted of
1,209 participants from 806 households; they had a mean
age of 43.2 years (range 5–94 years) and included 168
(12.4%) children 5–17 years of age. Compared to 2000
Cuyahoga County census demographics, our study sample
contained a significantly larger proportion of adults 18–64
years of age (75.7% vs. 63.5%), female participants
(57.8% vs. 52.8%), and African Americans (31.8% vs.
27.4%).
Initial screening identified WNVIgM and IgG antibody
in 4 serum samples, IgG only in 90 serum samples, and
IgM only in 2 specimens. Based on criteria listed in the
Table 2, confirmatory testing of the 96 samples identified
27 confirmed and 7 probable WNV-infected persons. The
countywide seroprevalence rate was 1.9% (95% CI
0.8–4.6) (Table 1), which suggests that 10,400–59,900 res-
idents were infected. Based on 155 WNND cases reported
from Cuyahoga County, ≈1 WNND case occurred for
every 160 infected persons (95% CI 1:67–1:386).
Seroprevalence varied significantly between age
groups (p<0.05) (Table 1). Based on reported WNND
cases and age-stratified seroprevalence rates, we estimate
that 1 case of WNND occurred per 4,167 infected children
5–17 years of age, per 154 infected adults 18–64 years of
age, and per 38 infected persons >65 years of age (Figure).
Strata-specific seroprevalence values ranged from 1.5% to
3.3% but were not statistically different (Table 1).
In 2002, Cuyahoga County experienced its largest epi-
demic of arboviral encephalitis and meningitis, yet only
1.9% of the county’s population became infected during
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Cuyahoga County, 155 cases of encephalitis and meningi-
tis (WNND incidence: 111 cases/million population)
occurred; the seroprevalence was 1.9% countywide and
2.5% in the selected highest risk survey stratum.
Little is known about WNV infection rates in children
(15). In contrast to a previous study (8), our study demon-
strated an age-dependent risk for WNV infection. The anti-
body prevalence in the 5- to 17-year age group was
significantly greater than in older age groups. These data
suggest that children were 4.5 times more likely to be
infected than older persons. In this study, children report-
ed spending more time outdoors and using less personal
protective measures, which likely contributed to their
higher seroprevalence rate. In 2002, only 4 cases of
WNND were reported in the 5- to 17-year age group,
resulting in a WNND:infection ratio of 1:4,200 compared
to a 1:38 ratio among persons >65 years of age. Thus, the
risk for WNND after infection may be as much as 110×
greater in adults >65 years of age, as compared to children.
Inclusion of a larger number of children in this study com-
pared to previous studies allowed these age-stratified
analyses to be completed.
Although WNV seroprevalence was similar to those
measured in previous outbreaks (7,8), our study was the
first to demonstrate that the risk for WNV infection can be
age-dependent. Children had a higher rate of infection than
adults, but serious neurologic disease developed in few of
them. This finding has implications for public health prac-
tice and emphasizes the need for children to use protective
measures to prevent mosquito bites to further lower their
risk for infection with WNV and other mosquitoborne
viruses. 
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